Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 22 | -1.50
Decreased by
-4.90%
|
-1.64
Increased by
+8.54%
|
| Aug 11, 22 | 5.58
Increased by
+418.86%
|
-1.33
Increased by
+519.55%
|
| May 12, 22 | -1.55
Increased by
+5.49%
|
-1.15
Decreased by
-34.78%
|
| Mar 24, 22 | -1.27
Increased by
+33.85%
|
-1.29
Increased by
+1.55%
|
| Nov 12, 21 | -1.43
Increased by
+31.90%
|
-1.47
Increased by
+2.72%
|
| Aug 12, 21 | -1.75
Increased by
+16.67%
|
-1.84
Increased by
+4.89%
|
| May 11, 21 | -1.64
Decreased by
-284.27%
|
1.69
Decreased by
-197.04%
|
| Mar 31, 21 | -1.92
Increased by
+19.33%
|
-1.22
Decreased by
-57.38%
|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 0.00
Decreased by
-100.00%
|
-7.64 M
Decreased by
-9.25%
|
Decreased by
N/A%
Decreased by
N/A%
|
| Jun 30, 22 | 0.00
Decreased by
-100.00%
|
28.01 M
Increased by
+453.13%
|
Increased by
+N/A%
Increased by
+N/A%
|
| Mar 31, 22 | 3.11 M
Increased by
+28.62%
|
-7.70 M
Decreased by
-6.08%
|
Decreased by
-247.17%
Increased by
+17.53%
|
| Dec 31, 21 | -2.54 M
Decreased by
-207.08%
|
-6.27 M
Decreased by
-88.83 K%
|
Increased by
+246.83%
Increased by
+83.15 K%
|
| Sep 30, 21 | 3.10 M
Increased by
+111.62%
|
-7.00 M
Decreased by
-3.03%
|
Decreased by
-226.00%
Increased by
+51.31%
|
| Jun 30, 21 | 3.11 M
Increased by
+557.51%
|
-7.93 M
Decreased by
-16.60%
|
Decreased by
-255.05%
Increased by
+82.27%
|
| Mar 31, 21 | 2.42 M
Increased by
+N/A%
|
-7.26 M
Decreased by
-350.47%
|
Decreased by
-299.71%
Decreased by
N/A%
|
| Dec 31, 20 | 2.37 M
Decreased by
-73.72%
|
-7.05 K
Increased by
+99.91%
|
Decreased by
-0.30%
Increased by
+99.67%
|
| Rank | ETF | Shares | Market Value | Weight % in ETF |
|---|
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.